GENTA INC DE/ Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2012-05: Study NCT01609127; Company role Lead sponsor; Phase Phase 2; Status Unknown.
- 2012-04: Study NCT01573468; Company role Lead sponsor; Phase Phase 2; Status Unknown.
- 2011-05: Study NCT01348009; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Unknown.
- 2011-04: Study NCT01337310; Company role Lead sponsor; Phase Phase 1; Status Unknown.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2012-05 | NCT01609127 Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer | Lead sponsor | Phase 2 | Unknown | Locally Advanced Non-resectable Breast Cancer; Metastatic Breast Cancer | 213 | 2014-07 |
| 2012-04 | NCT01573468 Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer | Lead sponsor | Phase 2 | Unknown | Gastric Carcinoma | 580 | 2014-08 |
| 2011-05 | NCT01348009 Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer | Lead sponsor | Phase 1, Phase 2 | Unknown | Gastric Carcinoma | 63 | 2014-01 |
| 2011-04 | NCT01337310 Study of Tesetaxel in Japanese Patients With Solid Tumors | Lead sponsor | Phase 1 | Unknown | Advanced Solid Tumors | 12 | 2012-09 |
| 2011-03 | NCT01315431 A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors | Lead sponsor | Phase 1 | Unknown | Solid Tumor | 9 | 2012-10 |
| 2011-02 | NCT01296243 Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer | Lead sponsor | Phase 2 | Unknown | Prostate Cancer | 57 | 2015-02 |
| 2010-12 | NCT01200342 Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma | Collaborator Lead: M.D. Anderson Cancer Center | Phase 2 | Terminated Results posted | Melanoma | 7 | 2013-09 |
| 2010-11 | NCT01221870 Tesetaxel as First-line Therapy for Metastatic Breast Cancer | Lead sponsor | Phase 2 | Unknown | Breast Neoplasm | 81 | 2013-01 |
| 2010-09 | NCT01215877 Tesetaxel for Previously Treated Patients With Bladder Cancer | Lead sponsor | Phase 2 | Unknown | Carcinoma, Transitional Cell | 33 | 2012-12 |
| 2010-06 | NCT01170975 Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules | Lead sponsor | Phase 1 | Completed | Solid Tumors | 12 | 2011-04 |
| 2010-03 | NCT01095120 Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer | Lead sponsor | Phase 2 | Unknown | Adenocarcinoma of the Stomach; Adenocarcinoma of Esophagogastric Junction | 27 | 2012-10 |
| 2010-02 | NCT01092585 Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH | Lead sponsor | Phase 2 | Unknown | Melanoma | 27 | 2012-03 |
| 2010-02 | NCT01064713 Phase II Study of Tesetaxel in Metastatic Melanoma | Collaborator Lead: M.D. Anderson Cancer Center | Phase 2 | Completed Results posted | Advanced Melanoma; Cancer | 17 | 2014-10 |
| 2008-07-23 | NCT00736450 Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma | Collaborator Lead: University of Nebraska | Early Phase 1 | Terminated Results posted | Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma | 37 | 2012-10-09 |
| 2008-07 | NCT00836173 Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Collaborator Lead: Loyola University | Phase 2 | Withdrawn | Diffuse Large B-cell Lymphoma | 0 | 2012-05 |
| 2007-07 | NCT00518895 Trial of Dacarbazine With or Without Genasense in Advanced Melanoma | Lead sponsor | Phase 3 | Completed | Melanoma | 300 | 2011-05 |
| 2007-05 | NCT00636545 Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors | Lead sponsor | Phase 1 | Completed | Solid Tumors | 25 | 2010-03 |
| 2006-11 | NCT00409383 Abraxane and Temodar Plus Genasense in Advanced Melanoma | Lead sponsor | Phase 1 | Unknown | Melanoma | 28 | 2013-06 |
| 2006-06 | NCT00517218 This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL) | Lead sponsor | Phase 3 | Withdrawn | Lymphocytic Leukemia | 2009-06 | |
| 2006-05 | NCT00543075 Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function | Lead sponsor | Phase 1 | Completed | Normal Renal Function; Mildly Impaired Renal Function; Moderately Impaired Renal Function | 23 | 2009-09 |
| 2006-04 | NCT00542893 A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine | Lead sponsor | Phase 1 | Completed | Advanced Melanoma | 2007-09 | |
| 2005-12 | NCT00543231 A Phase I Study of G3139 Subcutaneous in Solid Tumors | Lead sponsor | Phase 1 | Completed | Tumors | 8 | 2006-12 |
| 2005-08 | NCT00543205 Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment | Lead sponsor | Phase 2, Phase 3 | Terminated | Advanced Melanoma and Normal or Impaired; Hepatic Function | 6 | 2007-05 |
| 2003-11 | NCT00078234 Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | Lead sponsor | Phase 1, Phase 2 | Completed | Chronic Lymphocytic Leukemia | 25 | 2010-09 |
| 2002-06 | NCT00054808 Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma | Lead sponsor | Phase 2 | Completed | Non-Hodgkin's Lymphoma; Relapsed Lymphoma; Refractory Lymphoma; Low-Grade Lymphoma; Intermediate-Grade Lymphoma | 40 | |
| 2001-10 | NCT00030641 Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer | Lead sponsor | Phase 2, Phase 3 | Unknown | Lung Cancer | ||
| 2001-07 | NCT00024440 Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Lead sponsor | Phase 3 | Completed | Leukemia | 2007-02 | |
| 2001-01 | NCT00021749 Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | Lead sponsor | Phase 1, Phase 2 | Completed | Chronic Lymphocytic Leukemia; CLL | 40 | |
| 2000-12 | NCT00017602 Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma | Lead sponsor | Phase 3 | Completed | Multiple Myeloma and Plasma Cell Neoplasm | 2009-04 | |
| 2000-12 | NCT00017589 Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia | Lead sponsor | Phase 2 | Completed | Leukemia | 2006-05 | |
| 2000-07 | NCT00016263 Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma | Lead sponsor | Phase 3 | Completed | Melanoma (Skin) | 2004-12 |